The future of anti-CD20 monoclonal antibodies: are we making progress?
The future of anti-CD20 monoclonal antibodies: are we making progress?
复制标题
DOI：
10.1182/blood-2010-07-298356
复制
发表时间：
2011-03-17
期刊：
影响因子：
20.3
通讯作者：
Illidge, Tim M.
中科院分区：
文献类型：
--
作者：
Alduaij, Waleed;Illidge, Tim M.
抗CD 20单克隆抗体（mAb）利妥昔单抗彻底改变了B细胞恶性肿瘤的治疗。这一前所未有的成功不仅极大地改变了临床界对mAb改善结局能力的看法，而且激发了制药行业开发下一代抗CD 20 mAb的兴趣。自从15年前利妥昔单抗问世以来，我们已经了解了很多关于抗CD 20 mAb治疗效果的潜在机制。与此同时，许多新型抗CD 20 mAb已进入临床，每种mAb都设计有旨在进一步提高疗效的结构修饰。回顾进入临床试验的新一代抗CD 20 mAb，新的机制见解与这些下一代抗CD 20 mAb的开发之间的联系似乎尚不清楚。随着我们进入个性化医疗时代，在新兴的机制见解和临床开发之间建立更紧密的联系将变得越来越重要，以进一步增强抗CD 20 mAb的效力，超越利妥昔单抗的效力。（血。2011; 117（11）：2993-3001）
The anti-CD20 monoclonal antibody (mAb) rituximab has revolutionized the treatment of B-cell malignancies. This unprecedented success has not only substantially changed the mindset of the clinical community about the ability of mAb to improve outcomes but has catalyzed the interest in the pharmaceutical industry to develop the next generation of anti-CD20 mAbs. Since the introduction of rituximab 15 years ago, we have learned much about the potential mechanisms underlying the therapeutic efficacy of anti-CD20 mAbs. In parallel, many novel anti-CD20 mAbs have entered the clinic, each designed with modifications to structure aimed at further improving efficacy. On review of the newer generation of anti-CD20 mAbs entering clinical trials, it appears that the link between the novel mechanistic insights and the development of these next-generation anti-CD20 mAbs is unclear. As we move into an era of personalized medicine, it will become increasingly important for us to develop closer links between the emerging mechanistic insights and the clinical development, to further enhance the potency of anti-CD20 mAbs beyond that achieved with rituximab. (Blood. 2011; 117(11): 2993-3001)